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a b s t r a c t
Background: Heart-type fatty acid-binding protein (H-FABP) is an emerging biomarker, which
was found to be sensitive for the early diagnosis of acute myocardial infarction (AMI). We
prospectively investigated the usefulness of H-FABP determination for the evaluation of
acute chest pain in patients arriving at the emergency department.
Methods: Fifty-four patients presenting with acute ischemic chest pain were evaluated. H-FABP
was estimated at admission using latex-enhanced immunoturbidimetric assay. Serial cardiac
troponin I (cTnI), creatinine kinase-MB (CK-MB) determination, ischemia workup with stress
testing, and/or coronary angiogram (CAG) were performed according to standard protocols.
Results: The sensitivity and speciﬁcity of H-FABP was 89.7% and 68%, for cTnI it was 62.1%
and 100%, and for CK-MB it was 44.8% and 92%, respectively for diagnosis of AMI. The
sensitivity of H-FABP was found to be far superior to initial cTnI and CK-MB, for those seen
within 6 h (100% vs. 46.1%, 33% respectively). On further evaluation of patients with positive
H-FABP and negative cTnI, 71.4% of the patients had signiﬁcant lesion on CAG, indicating
ischemic cause of H-FABP elevation. Six patients with normal cTnI and CK-MB with high
H-FABP had ST elevation on subsequent ECGs and were taken for primary angioplasty.
Conclusion: H-FABP is a highly sensitive biomarker for the early diagnosis of AMI. H-FABP as
early marker and cTnI as late marker would be the ideal combination to cover the complete
diagnostic window for AMI. Detection of myocardial injury by H-FABP may also be applied
in patients with unstable angina. H-FABP can also be used as a marker for early detection
of STEMI before the ECG changes become apparent.
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The clinical evaluation, triage, and management of patients
with possible acute coronary syndromes (ACS) present a
substantial medical and ﬁscal challenge.
Cardiac troponin (cTn) is recommended as the preferred
biomarker for early risk stratiﬁcation.1 cTn may not rise for the
ﬁrst 6 h after the onset of symptoms and, if negative, should be
repeated within 8–12 h after the onset of pain.1
Application of an early biomarker potentially reduces
diagnostic uncertainty in patients suspected of an ACS. This
may lead to a reduction in unnecessary ICU admissions,
patient's ﬁnancial burden, hospital resources, and healthcare
costs. Moreover, a diagnosis of ACS can be established much
earlier than with troponin, which may result in earlier
initiation of appropriate treatment, including revasculariza-
tion procedures.
Heart-type fatty acid-binding protein (H-FABP) is a novel
biomarker shown to be released from injured myocardium and
detected in blood within 1 h after onset of ischemia.2 Several
studies have shown that it is a sensitive early marker of
myocardial injury.3–8
This study was designed to evaluate the efﬁcacy of serum
H-FABP measurement for triaging of patients presenting to the
emergency department with chest pain, in comparison to
cardiac troponin I (cTnI) and creatinine kinase-MB (CK-MB).
2. Materials and methods
2.1. Study design
The study is a prospective observational study conducted in
Amrita Institute of Medical Sciences, Kerala, India. The study
was approved by the institutional ethical committee. From
August 2013 to July 2014, 77 patients with acute chest pain
presenting to the emergency department were enrolled and
their data entered into a clinical database after obtaining
informed, written consent. Inclusion criteria included men
and women aged 18 years or older, with chest pain suggestive
of cardiac ischemia at the discretion of the treating cardiolo-
gist. Patients with non-cardiac chest pain, renal insufﬁciency
with an estimated glomerular ﬁltration rate (eGFR) <60 ml/
min, symptoms temporally related to direct local trauma of <3
days, ECG changes suggestive of STEMI at presentation, new
onset dysrhythmia excluding sinus tachycardia, new onset
congestive heart failure, acute pulmonary edema, recent
cardiopulmonary resuscitation, liver disease, and sepsis were
excluded from the study.
Important deﬁnitions related to inclusion and exclusion
criteria are as follows: chest pain suggestive of coronary origin
is deﬁned, in accordance with ACC/AHA guidelines,1 as chest
or left arm pain as the chief symptom. Non-cardiac chest pain
is deﬁned at the discretion of the cardiologist after evaluation
using radiography or other technical assessments. Acute
myocardial infarction (AMI) was diagnosed if there is
biochemical evidence of cardiac myocyte necrosis in the
appropriate clinical setting as per the ESC/ACCF/AHA/WHF
universal deﬁnition of myocardial infarction.9 Patients withreduced renal clearance (eGFR <60 ml/min) were excluded due
to higher pre-infarct baseline H-FABP levels.4 Patients with a
history of trauma less than 3 days were excluded due to
potential elevation in H-FABP with muscle injury. Patients
with ST elevation on ECG, heart failure, dysrhythmias,
pulmonary edema, hypotension, or cardiopulmonary resusci-
tation were excluded due to potential early triaging and a
potential inability to follow these patients throughout the
study period.
2.2. Study protocol
Information regarding patient demographics and relevant
clinical data, such as that concerning the patient's cardiac
history and contact address, was recorded on a data collection
sheet. Blood samples were taken upon arrival to the Casualty.
All blood tubes for biomarker determination were obtained
using clot activator tubes, centrifuged immediately at
3000 rpm for 5 min, and the serum was analyzed.
2.3. Tests
A latex-enhanced immunoturbidimetric assay via Olympus
AU2700 for H-FABP was used, with an upper limit of normal of
6.4 ng/L as recommended by the manufacturer (Randox
Laboratories, UK). H-FABP was estimated only at admission.
cTnI was measured using Abbott Architect-Chemilumines-
cence method on admission, and at 6th and 12th hours post-
admission as part of the standard chest pain protocol, and a
cut-off value of 0.14 ng/ml was taken with a 99th percentile
reference range as recommended by ACC/AHA.1 A diagnosis of
myocardial infarction was made if cTnI measured 12 h after
admission was greater than the upper limit of normal. Serum
CK-MB was estimated by photometric method on admission,
and at 6th and 12th hours post-admission as part of the
standard chest pain protocol along with cTnI.
Possible myocardial ischemia was evaluated with myocar-
dial stress imaging and/or coronary angiography. Stress test
was performed in conjunction with ECHO imaging. Coronary
angiography was carried out in those patients with positive
stress testing or those patients deemed to have a high-pretest
probability for coronary artery disease (CAD) based on
subsequent cTnI results. All angiographic images were
reviewed by experienced cardiologists. A positive coronary
angiography is deﬁned as stenosis resulting in ≥50% diameter
reduction in any major epicardial vessel. Final diagnosis was
based on the discharge diagnosis documented on discharge
summaries.
2.4. Statistics
Continuous variables were presented as mean  SD, and
categorical variables as frequencies (percentages). Compar-
isons for categorical variables were performed using McNemer
test. The sensitivity, speciﬁcity, and positive and negative
predictive values were calculated to assess the diagnostic
accuracy of H-FABP, cTnI, and CK-MB in the exclusion of ACS
on admission and at 6th and 12th hours post-admission for
cTnI and CK-MB. Sensitivity of H-FABP, cTnI1, and CK-MB1 was
compared using Z-test statistic for proportion. All statistical
Table 1 – Risk factors (n = 54).
Risk factors n %
Severe angina 8 14.8
Family history of CAD 7 13.0
Hypertension 34 63.0
Dyslipidemia 31 57.4
Type 2 DM 34 63.0
Current smoker 2 3.7
Known case of CAD 25 46.3
Aspirin use with in last 24 h 24 44.4
ST deviation 23 42.6
Increased markers (standard markers) 29 53.7
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software package (IBM SPSS Statistics for Windows, Version
20.0; Armonk, NY: IBM Corp).
3. Results
Seventy-seven patients were evaluated in the casualty and H-
FABP was estimated. 23 patients were excluded from the study
after further evaluation because of the various causes (renal
failure, liver disease, sepsis, etc.). The mean age was 63.4
 11.5 years and 68.5% were men. The risk factors are
summarized in Table 1. Hypertension, type 2 diabetes, and
history of CAD account for 63%, 63%, and 46.3%, respectively.
TIMI risk score for unstable angina/NSTEMI was calculated
based on the risk factors on presentation. 25.9% of patients had
TIMI risk score of 2. Majority of the patients had TIMI risk scoreTable 2 – Comparison of admission cardiac markers with relat
Durati
≤6 h (n = 29) >
H-FABP cTnI CK-MB H-FABP 
Sensitivity 100% 46.1% 33.3% 78.6% 
Speciﬁcity 85.7% 100% 92.9% 45.5% 
Accuracy 93.1% 72.4% 62.1% 64% 
PPV 88.2% 100% 83.3% 64.7% 
NPV 100% 63.6% 56.5% 62.5% 
H-FABP, heart-type fatty acid-binding protein; cTnI, cardiac troponin I;
negative predictive value.
Table 3 – Comparison of cardiac markers serially done after ad
On hospital admission (n = 54) 
H-FABP cTnI CK-MB 
Sensitivity 89.7% 62% 44.8% 
Speciﬁcity 68% 100% 92% 
Accuracy 79.6% 79.6% 66.7% 
PPV 76.5% 100% 86.7% 
NPV 85% 69.4% 59% 
H-FABP was estimated only on admission and was not repeated thereafte
gold standard and hence the 100% accuracy. H-FABP, heart-type fatty aci
MB; PPV, positive predictive value; NPV, negative predictive value.between 2 and 4. 53.7% of patients presented within 6 h of
onset of chest pain. Though majority of patients were clear
about the history of duration of pain, few patients gave history
of vague pain, which had started few days previously and
increased gradually. In such patients, the time from onset of
initial chest discomfort was taken as duration of chest pain. 15
(27.8%) patients had regional wall motion abnormality on
echocardiography. Coronary angiogram (CAG) was done in 40
(74.1%) patients.
Only patients with NSTEMI, positive stress test, or patients
with high-clinical suspicion underwent CAG. Out of the 40
patients who underwent CAG, 32 (59.3%) patients had
signiﬁcant disease. Table 2 summarizes the sensitivity,
speciﬁcity, accuracy, positive predictive value (PPV), and
negative predictive value (NPV) of H-FABP, cTnI, and CK-MB
on admission with relation to duration of chest pain.
The sensitivity of H-FABP was found to be superior to initial
cTnI (89.7% vs. 62.1%, Z = 4.61, p < 0.01) and CK-MB (89.7% vs.
44.8%, Z = 6.90, p < 0.01). In patients presenting within 6 h after
onset of chest pain, the sensitivity of H-FABP was found to be
far superior to initial cTnI (100% vs. 46.1%, Z = 8.93, p < 0.01),
and CK-MB (100% vs. 33.3%, Z = 10.40, p < 0.01), but the
speciﬁcity of H-FABP for AMI was poor (68%). Table 3
summarizes sensitivity and speciﬁcity of various markers
serially done after admission.
In ﬁve out of the seven patients with positive H-FABP and
negative cTnI, CAG was done based on either positive stress
test or high-clinical suspicion of CAD. All the 5 patients had
signiﬁcant lesion on CAG indicating ischemic cause of H-FABP
elevation. Rest of the 2 patients had a negative stress test.ion to duration of chest pain (n = 54).
on of chest pain
6 h (n = 25) Total (n = 54)
cTnI CK-MB H-FABP cTnI CK-MB
78.6% 57.1% 89.7% 62.1% 44.8%
100% 90.9% 68% 100% 92.0%
88% 72% 79.6% 79.6% 66.7%
100% 88.9% 76.5% 100% 86.7%
78.6% 62.5% 85% 69.4% 59%
 CK-MB, creatinine kinase-MB; PPV, positive predictive value; NPV,
mission (n = 54).
6 h after hospital
admission (n = 54)
12 h after hospital
admission (n = 54)
cTnI CK-MB cTnI CK-MB
96.6% 75.9% 100% 79.3%
100% 96% 100% 92%
98.1% 85.2% 100% 85.2%
100% 95.7% 100% 92%
96.2% 77.4% 100% 79.3%
r. cTnI estimated 12 h after hospital admission was assumed to be the
d-binding protein; cTnI, cardiac troponin I; CK-MB, creatinine kinase-
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Early diagnosis of AMI facilitates rapid and appropriate triage
of patients within the Accident and Emergency department,
helping to prevent inadvertent discharge of patients with AMI.
It also avoids delay in administering treatment for AMI, and
reduces the possibility of patients without AMI given treat-
ments from which they will not beneﬁt, and which have the
potential to cause signiﬁcant harm. The 12-lead ECG is an
important tool for early detection of AMI, but it has signiﬁcant
limitations, e.g., LBBB or a permanent pacemaker may make
interpretation impossible and ECG changes may not be
apparent early in the course of the disease. Another signiﬁcant
factor is that interpretation of the 12-lead ECG is dependent on
the experience of the physician.10
AMI is diagnosed if there is biochemical evidence of cardiac
myocyte necrosis in the appropriate clinical setting.9 Cardiac
troponins have assumed an important role in modern
cardiology practice, both in diagnosis of AMI and in risk
stratiﬁcation of patients with acute chest pain. A major
drawback with cardiac troponins is that they are released
relatively slowly from damaged myocytes.11 This study
conﬁrms the limitation of sampling cardiac troponin at the
time of admission for patients presenting with acute ischemic-
type chest pain. The sensitivity of initial cTnI on admission
was 62%. The sensitivity of initial troponin was at its lowest for
patients who presented within 6 h of symptom onset (46.1%)
(Table 2). It increased with increasing time from symptom
onset to admission, with a sensitivity of 78.6% for patients who
presented after 6 h of onset of chest pain. This leaves a false
negative rate of 21.4% for the initial cTnI even in patients who
presented 6 h after the onset of chest pain (i.e., subsequent
cTnI sampled later from admission becoming positive)
(Table 3). These ﬁndings were similar to a study by McCann
et al. where the sensitivity of initial cardiac troponin T (cTnT)
for AMI was found to be 75%. The sensitivity of initial cTnT for
patients who presented within 4 h of symptom onset was
55%.14
This study has demonstrated that, of all the investigational
biomarkers, H-FABP has a potential role in the very early
diagnosis of AMI. There has been interest in H-FABP as a
biochemical marker of myocardial injury since 1988, when it
was demonstrated to be released from injured myocardium.12
The release characteristics of H-FABP after AMI show that a
rise is detectable as early as 1 h after symptom onset, a peak
level is reached after 2–4 h, and due to rapid renal clearance,
the level returns to baseline within 16–24 h.2,13 Several studies
reporting the usefulness of H-FABP as an early marker of AMI
pre-dated the widespread use of cardiac troponins.3–8 Data for
the diagnostic performance of admission of H-FABP using the
modern deﬁnition of AMI are limited.
Our study has demonstrated that measurement of H-FABP
in patients with acute ischemic-type chest pain at the time of
admission is useful and complements the subsequent
measurement of cardiac troponin. The sensitivity and speci-
ﬁcity of H-FABP in our study were 89.7% and 68%, respectively.
The sensitivity of H-FABP is superior to initial cTnI for those
seen within 6 h (100% vs. 46.1%%, Z = 8.93, p < 0.01), but the
speciﬁcity of H-FABP for AMI was poor (68%) (Table 2). Thespeciﬁcity of H-FABP for AMI reported in previous studies
varies from 49% to 86%.3–8,14,15 In a study by Chan et al., H-FABP
had better sensitivity and NPV on admission (72% and 67%,
respectively) than cTn (51% and 51%, respectively). Further-
more, the sensitivity and NPV of H-FABP increased to 100% for
samples taken 1 h after admission.15 A study by Ruzgar et al.4
showed 38% sensitivity with troponin, 76% sensitivity with CK-
MB, and 95% sensitivity with H-FABP in patients admitted
within 6 h of chest pain onset. Within 6–24 h, sensitivity of
troponin and CK-MB increased to 100 and 90% respectively,
while that of H-FABP was 91%.
The sensitivity of H-FABP was also found to be superior to
CK-MB in the early diagnosis of AMI in the present study. The
sensitivity of CK-MB in our study was found to be 44.8%. In
patients who presented within 6 h, the sensitivity was even
lower (33.3%), whereas the speciﬁcity of CK-MB was higher
compared to H-FABP (92% vs. 68%) (Table 2). Recently, a high-
sensitivity troponin T (hsTnT) assay has been developed,
permitting measurement of concentrations that are 10-fold
lower than those measurable with conventional assays.16,17
Though hsTnT assay offers excellent diagnostic performance
to rule out ACS, a recent study by Inoue et al. showed that it is
prone to more false-positive results compared to H-FABP with
similar overall diagnostic performance.18
The reason for the relatively poor speciﬁcity of H-FABP in
the current study may relate to a number of factors. Firstly, H-
FABP was estimated in all the patients regardless of the
duration of chest pain. As the level returns to base-line within
20 h due to rapid renal clearance, it is unlikely to be positive in
patients presenting after 20 h of chest pain onset unless they
had a re-infarct. Though the overall speciﬁcity was only 68%,
the speciﬁcity in patients presenting within 6 h of chest pain
was 85.7%, indicating that the low speciﬁcity is due to plasma
kinetics (Table 2). Secondly, H-FABP may be released from
ischemic myocardium, as well as infarcted myocardium. In
our study on further evaluation, ﬁve out of the seven patients
with positive H-FABP and negative cTnI had signiﬁcant lesion
on CAG indicating ischemic cause of H-FABP elevation.
Thirdly, H-FABP is present, albeit at lower concentrations, in
skeletal muscle. In this study, no data were collected on recent
physical exercise, recent injury, or recent intramuscular
injections.
Out of the 54 patients included in the study, 6 patients with
normal cTnI and CK-MB with high H-FABP at presentation had
new onset ST elevation, 1–2 h after hospital admission, and
underwent primary angioplasty. These results indicate the
potential for H-FABP for early diagnosis of STEMI even before
the ECG changes develop. All these patients had very high H-
FABP values (>100) with normal troponin and CK-MB.
4.1. Limitations
A limitation of this study is that recruitment took place at the
time of admission from casualty of a tertiary care hospital with
cardiology specialization. This is reﬂected in the relatively
high incidence of AMI (53.7%). As a consequence, the results
presented may not necessarily be applicable to lower risk
populations, such as all patients with chest pain presenting to
the Accident and Emergency department. Another limitation
is that this study only assessed the potential beneﬁt from a
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 5 3 8 – 5 4 2542single measurement of H-FABP at the time of admission.
Sequential measurements were not investigated. Myoglobin
was not measured for comparison purposes. Unlike myoglo-
bin, the concentration of H-FABP in cardiac muscle is higher
than in skeletal muscle.10 This may mean that H-FABP is
potentially more suitable than myoglobin as an early marker
of myocyte injury. This study was designed taking cTnI done
after 12 h of admission as a gold standard for diagnosis of AMI
though it is not 100% speciﬁc.
4.2. Conclusions
H-FABP is one of the promising new biomarkers for myocardial
tissue injury detection. H-FABP is a highly sensitive biomarker
for acute ischemia and infarction. Measurement of H-FABP in
patients with acute ischemic-type chest pain at the time of
admission will assist in the early diagnosis of AMI. For patients
presenting within 6 h of symptom onset, the sensitivity of H-
FABP is signiﬁcantly higher than cTnI and CK-MB. Cardiac
troponins are speciﬁc but rather late markers for detection of
AMI. H-FABP as early marker and cTnI as late marker would be
the ideal combination to cover the complete diagnostic
window for AMI. However, the speciﬁcity of H-FABP alone
for diagnosis of acute MI is poor. H-FABP elevation was also
found in patients with chest pain and signiﬁcant stenosis on
CAG without myocardial infarction. This sensitive detection of
myocardial ischemia by H-FABP may also be applied in
patients with unstable angina though further studies are
required. H-FABP can also be used as a marker for early
detection of STEMI before the ECG changes become apparent.
Conﬂicts of interest
The authors have none to declare.
Acknowledgments
We thank Dr. Prem Nair, Medical Director; Dr. Prathapan Nair,
Principal; and Dr. Sanjeev Singh, Medical Superintendent,
Amrita Institute of Medical Sciences, Kochi for the research
grant. We thank Dr. K.R. Sundaram and Mr. Abish for their help
in statistical analysis. We also thank all the consultants,
residents, and staff of the Department of Cardiology and
Biochemistry for their valuable support.
r e f e r e n c e s
1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007
guidelines for the management of patients with unstable
angina/non-ST-elevation myocardial infarction. J Am Coll
Cardiol. 2007;50:e1–e157.
2. Sohmiya K, Tanaka T, Tsuji R, et al. Plasma and urinary
heart-type cytoplasmic fatty acid-binding protein incoronary occlusion and reperfusion induced myocardial
injury model. J Mol Cell Cardiol. 1993;25:1413–1426.
3. Nakata T, Hashimoto A, Hase M, et al. Human heart-type
fatty acid-binding protein as an early diagnostic and
prognostic marker in acute coronary syndrome. Cardiology.
2003;99:96–104.
4. Ruzgar O, Bilge AK, Bugra Z, et al. The use of human heart-
type fatty acid-binding protein as an early diagnostic
biochemical marker of myocardial necrosis in patients with
acute coronary syndrome, and its comparison with
troponin-T and creatine kinase-myocardial band. Heart
Vessels. 2006;21:309–314.
5. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding
proteins as plasma markers of tissue injury. Clin Chim Acta.
2005;352:15–35.
6. Ishii J, Wang JH, Naruse H, et al. Serum concentrations of
myoglobin vs human heart-type cytoplasmic fatty acid-
binding protein in early detection of acute myocardial
infarction. Clin Chem. 1997;43:1372–1378.
7. Okamoto F, Sohmiya K, Ohkaru Y, et al. Human heart-type
cytoplasmic fatty acid-binding protein (H-FABP) for the
diagnosis of acute myocardial infarction. Clinical evaluation
of H-FABP in comparison with myoglobin and creatine
kinase isoenzyme MB. Clin Chem Lab Med. 2000;38:231–238.
8. Ghani F, Wu AH, Graff L, et al. Role of heart-type fatty acid-
binding protein in early detection of acute myocardial
infarction. Clin Chem. 2000;46:718–719.
9. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF
Task Force for the Redeﬁnition of Myocardial Infarction.
Universal deﬁnition of myocardial infarction. Eur Heart J.
2007;28:2525–2538.
10. Salerno SM, Alguire PC, Waxman HS. Competency in
interpretation of 12-lead electrocardiograms: a summary
and appraisal of published evidence. Ann Intern Med.
2003;138:751–760.
11. Panteghini M, Pagani F, Bonetti G. The sensitivity of cardiac
markers: an evidence-based approach. Clin Chem Lab Med.
1999;37:1097–1106.
12. Glatz JF, van Bilsen M, Paulussen RJ, et al. Release of fatty
acid-binding protein from isolated rat heart subjected to
ischemia and reperfusion or to the calcium paradox. Biochim
Biophys Acta. 1988;961:148–152.
13. Alhadi HA, Fox KAA. Heart-type fatty acid-binding protein in
the early diagnosis of acute myocardial infarction: the
potential for inﬂuencing patient management. Sultan Qaboos
Univ Med J. 2010;10:41–49.
14. McCann CJ, Glover BM, Menown IB, et al. Novel
biomarkers in early diagnosis of acute myocardial infarction
compared with cardiac troponin T. Eur Heart J. 2008;29:
2843–2850.
15. Chan CP, Sanderson JE, Glatz JF, et al. A superior early
myocardial infarction marker. Human heart-type fatty acid-
binding protein. Z Kardiol. 2004;93:388–397.
16. Mingels A, Jacobs L, Michielsen E, et al. Reference population
and marathon runner sera assessed by highly sensitive
cardiac troponin T and commercial cardiac troponin T and I
assays. Clin Chem. 2009;55:101–108.
17. Melanson SE, Morrow DA, Jarolim P. Earlier detection of
myocardial injury in a preliminary evaluation using a new
troponin I assay with improved sensitivity. Am J Clin Pathol.
2007;28:282–286.
18. Inoue K, Suwa S, Ohta H, et al. Heart fatty acid-binding
protein offers similar diagnostic performance to high-
sensitivity troponin T in emergency room patients
presenting with chest pain. Circ J. 2011;75:2813–2820.
